ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000.

This should not be seen as good news for any given technology (iFR, in this case), but for physiologic assessment as a general concept. Many more interventional cardiologists need to start using physiologic assessment as a standard course of action in their cath labs, because there is much evidence that it improves outcomes.

 

FFR requires maximum hyperemia, which is achieved by using adenosine—with its associated side effects and costs. On the other hand, iFR calculates the pressure gradient of a lesion during diastole, immediately after the dicrotic wave, when physiologic resistance is minimum. That renders unnecessary the use of hyperemic agents.


Read also: NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising.


Last year, DEFINE-FLAIR and iFR-SWEDEHEART results proved the noninferiority of iFR in terms of events compared with FFR measurement.

 

The difference in terms of costs is driven by the fact that FFR-guided procedures identified more significant lesions that required treatment. More time must go by for the assessment of this aspect. If, in the future, some lesions left untreated with iFR require reintervention, the equation might be inverted by the late catch-up phenomenon. The opposite might also turn out to be true: less stenting with iFR might derive in less restenosis and less future thrombosis.

 

Original title: Comparative Cost-Effectiveness of the Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Coronary Revascularization Decision-Making.

Presenter: Patel MR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...